Ariad Pharmaceuticals (ARIA) 6.87 $ARIA
ARIAD & Angelini Team Up to Commercialize Iclusig in Europe - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 1:35PM CST
ARIAD Pharmaceuticals, Inc. (ARIA) announced that it has granted exclusive rights to privately-held pharmaceutical company Angelini Pharma to commercialize Iclusig in Central and Eastern Europe.
ARQL: 1.22 (+0.08), SCMP: 14.28 (+0.39), ARIA: 6.87 (+0.05), BIOD: 1.33 (-0.04)
Striking Deals on Street: New Research on State Investors, NCI, Ariad, Under Armour and Meadowbrook
PR Newswire - Wed Dec 31, 8:20AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including State Investors (NASDAQ: SIBC), NCI (NASDAQ: NCIT), Ariad (NASDAQ: ARIA), Under Armour (NYSE: UA), and Meadowbrook (NYSE: MIG). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
UA: 67.90 (-0.43), SIBC: 20.72 (+5.36), ARIA: 6.87 (+0.05), NCIT: 10.21 (-0.07), MIG: 8.46 (+1.33)
IPO enables Bellicum to accelerate pay off of license to Ariad
Seeking Alpha - at Seeking Alpha - Tue Dec 30, 3:38PM CST
BLCM: 23.04 (+0.04), ARIA: 6.87 (+0.05)
Ariad inks Iclusig distribution deal for Central and Eastern Europe
Seeking Alpha - at Seeking Alpha - Tue Dec 30, 6:55AM CST
ARIA: 6.87 (+0.05)
ARIAD Announces Commercialization Agreement for Iclusig in Seven Central and Eastern European Countries
Business Wire - Tue Dec 30, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Angelini Pharma, through the Austrian subsidiary CSC Pharmaceuticals, today announced that ARIAD has granted Angelini exclusive rights to commercialize Iclusig(R) (ponatinib) for the indications approved by the European Medicine Agency (EMA) in Central and Eastern Europe. These countries include Bulgaria, the Czech Republic, Hungary, Poland, Romania, Slovakia and Slovenia. With this distributorship in place, Iclusig will be available to patients with resistant and intolerant Philadelphia-positive leukemias in more than 23 countries in Europe.
ARIA: 6.87 (+0.05)
China Biotech Week In Review: Otsuka Buys Rights To ARIAD's Leukemia Drug
ChinaBio Today - at Seeking Alpha - Sun Dec 28, 11:30AM CST
Deals and Financings Otsuka Pharma (TYO: 4768) of Japan snagged marketing rights to Iclusig, a leukemia drug developed by ARIAD Pharmaceuticals (NASDAQ: ARIA ), for Japan, China and eight other Asian countries (see story ). Otsuka will pay $77.5...
CRME: 9.25 (+0.19), ARIA: 6.87 (+0.05)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 8:18AM CST
CYTK: 8.01 (+1.11), JRJC: 5.32 (-0.24), RDN: 16.72 (-0.11), CHK: 19.57 (-0.07), VNDA: 14.32 (-0.19), DRL: 3.95 (-0.09), ARIA: 6.87 (+0.05), ICLD: 2.92 (-0.02), NQ: 3.91 (-0.10)
Ariad Pharma inks commercialization deal in Asia
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 6:43AM CST
ARIA: 6.87 (+0.05)
ARIAD and Otsuka Announce Co-Development and Commercialization Agreement for Iclusig to Treat Leukemias in Japan and Nine Other Asian Countries
Business Wire - Tue Dec 23, 6:00AM CST
--Otsuka to obtain rights in ten Asian countries to Iclusig, a newest-generation treatment for patients with refractory chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia
ARIA: 6.87 (+0.05)
ARIAD To Present at The 33rd Annual J.P. Morgan Healthcare Conference
Business Wire - Mon Dec 22, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the 33rd Annual J.P. Morgan Healthcare Conference being held in San Francisco. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company's business on Wednesday, January 14 at 3:00 p.m. (PT).
JPM: 62.58 (-0.57), ARIA: 6.87 (+0.05)
Adam Feuerstein's 2014 Biotech Stock Report Card (No Grading on a Curve)
at The Street - Fri Dec 19, 8:02AM CST
Good calls: Vertex, InterMune, Chelsea, Galena, Exact Sciences. The bad calls: Avanir, Amarin, Exelixis and the bursting biotech stock bubble.
VRTX: 118.80 (-0.35), GALE: 1.51 (-0.01), EXAS: 27.44 (-1.09), ARIA: 6.87 (+0.05), MNKD: 5.22 (-0.13)
Biotech Stocks Technical Insight -- ARIAD Pharma, Geron, PDL BioPharma, Cytori Therapeutics, and Navidea Biopharma
PR Newswire - Thu Dec 18, 8:15AM CST
Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Geron Corporation (NASDAQ: GERN), PDL BioPharma Inc. (NASDAQ: PDLI), Cytori Therapeutics Inc. (NASDAQ: CYTX), and Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Wednesday, December 17, 2014, surged as the Dow Jones Industrial Average finished at 17,356.87, up 1.69% and the NASDAQ Composite closed at 4,644.31, up 2.12%. The S&P 500 finished the session 2.04% higher at 2,012.89. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Index ended the day at 791.66, up 1.90%, with the index advancing 6.28% in the previous three months. Register for your complimentary reports on these five stocks at:
NAVB: 1.89 (+0.06), CYTX: 0.49 (+0.02), GERN: 3.25 (+0.04), ARIA: 6.87 (+0.05), PDLI: 7.71 (unch)
Does George Soros Think Biotech's Bull Run Is Finally Coming to an End?
George Budwell, The Motley Fool - Motley Fool - Mon Dec 15, 6:45AM CST
To say that biotech stocks have performed well as a group over the last two years is an understatement; they have absolutely crushed the broader markets. For example, the iShares Nasdaq Biotech Index has more than tripled the performance of the ...
SRPT: 14.47 (-0.05), IBB: 303.35 (-1.27), ARIA: 6.87 (+0.05), CELG: 111.86 (-1.68)
SmarTrend Watching for Potential Rebound in Shares of Ariad Pharmaceuticals After 7.76% Loss
Comtex SmarTrend(R) - Thu Dec 11, 4:40PM CST
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $6.34 to a high of $6.88. Yesterday, the shares fell 7.8%, which took the trading range below the 3-day low of $6.80 on volume of 13.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ARIA: 6.87 (+0.05)
Energy Stocks Pare Gains as Crude Oil Closes Below $60 For First Time in Five Years
at The Street - Thu Dec 11, 1:52PM CST
Energy stocks are leading the markets higher, a day after they sparked a selloff.
SPLS: 18.12 (+0.09), DAL: 49.19 (-0.04), XOM: 92.45 (-0.57), COP: 69.06 (-0.87), LLY: 68.99 (-0.65), LULU: 55.79 (+0.04), LUV: 42.32 (+0.15), URBN: 35.13 (+0.06), EBAY: 56.12 (-1.10), AAL: 53.63 (+0.21), ODP: 8.57 (-0.04), ARIA: 6.87 (+0.05), CVX: 112.18 (-0.93), WAG: 76.05 (-0.49), XLE: 79.16 (-0.60)
Nasdaq stocks posting largest percentage decreases
AP - Thu Dec 11, 12:19PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
AMBA: 50.72 (-1.68), LNCO: 10.37 (+0.13), MCEP: 6.31 (+0.53), LAKE: 9.37 (-0.18), CLDN: 19.53 (-0.11), BRID: 7.75 (+0.38), ARIA: 6.87 (+0.05), LINE: 10.13 (+0.04), MIND: 5.93 (-0.06), DGLY: 15.32 (-0.56), ALLT: 9.18 (+0.20), ROSE: 22.31 (+0.28)
Ariad slumps after analyst downgrade
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 9:25AM CST
IBB: 303.35 (-1.27), ARIA: 6.87 (+0.05)
Will Ariad Pharmaceuticals (ARIA) Stock be Affected Today by This Analyst Action?
at The Street - Thu Dec 11, 8:14AM CST
Shares of Ariad Pharmaceuticals (ARIA) are down after Credit Suisse downgraded the global oncology company to 'underperform' from 'neutral' and lowered its price target to $6 from $8.
ARIA: 6.87 (+0.05)
Downgrade Alert for Ariad Pharmaceuticals (ARIA)
Comtex SmarTrend(R) - Thu Dec 11, 6:54AM CST
Ariad Pharmaceuticals (NASDAQ:ARIA) was downgraded from Neutral to Underperform at Credit Suisse today. The stock closed yesterday at $7.02 on volume of 4.6 million shares, below average daily volume of 6.3 million. In the past 52 weeks, Ariad Pharmaceuticals share prices have been bracketed by a low of $3.80 and a high of $9.83 and closed yesterday at $7.02, 85% above that low price. Over the last five market days, the 200-day moving average (MA) has gone down 0.3% while the 50-day MA has advanced 1.5%.
ARIA: 6.87 (+0.05)
Uptrend Call Working As Ariad Pharmaceuticals Stock Rises 22.6% (ARIA)
Comtex SmarTrend(R) - Tue Dec 09, 5:08PM CST
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on October 29th, 2014 at $5.92. In approximately 1 month, Ariad Pharmaceuticals has returned 22.57% as of today's recent price of $7.25.
ARIA: 6.87 (+0.05)
ARIAD & Angelini Team Up to Commercialize Iclusig in Europe - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 1:35PM CST
ARIAD Pharmaceuticals, Inc. (ARIA) announced that it has granted exclusive rights to privately-held pharmaceutical company Angelini Pharma to commercialize Iclusig in Central and Eastern Europe.
ARQL: 1.22 (+0.08), SCMP: 14.28 (+0.39), ARIA: 6.87 (+0.05), BIOD: 1.33 (-0.04)
Striking Deals on Street: New Research on State Investors, NCI, Ariad, Under Armour and Meadowbrook
PR Newswire - Wed Dec 31, 8:20AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including State Investors (NASDAQ: SIBC), NCI (NASDAQ: NCIT), Ariad (NASDAQ: ARIA), Under Armour (NYSE: UA), and Meadowbrook (NYSE: MIG). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
UA: 67.90 (-0.43), SIBC: 20.72 (+5.36), ARIA: 6.87 (+0.05), NCIT: 10.21 (-0.07), MIG: 8.46 (+1.33)
IPO enables Bellicum to accelerate pay off of license to Ariad
Seeking Alpha - at Seeking Alpha - Tue Dec 30, 3:38PM CST
BLCM: 23.04 (+0.04), ARIA: 6.87 (+0.05)
Ariad inks Iclusig distribution deal for Central and Eastern Europe
Seeking Alpha - at Seeking Alpha - Tue Dec 30, 6:55AM CST
ARIA: 6.87 (+0.05)
ARIAD Announces Commercialization Agreement for Iclusig in Seven Central and Eastern European Countries
Business Wire - Tue Dec 30, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Angelini Pharma, through the Austrian subsidiary CSC Pharmaceuticals, today announced that ARIAD has granted Angelini exclusive rights to commercialize Iclusig(R) (ponatinib) for the indications approved by the European Medicine Agency (EMA) in Central and Eastern Europe. These countries include Bulgaria, the Czech Republic, Hungary, Poland, Romania, Slovakia and Slovenia. With this distributorship in place, Iclusig will be available to patients with resistant and intolerant Philadelphia-positive leukemias in more than 23 countries in Europe.
ARIA: 6.87 (+0.05)
China Biotech Week In Review: Otsuka Buys Rights To ARIAD's Leukemia Drug
ChinaBio Today - at Seeking Alpha - Sun Dec 28, 11:30AM CST
Deals and Financings Otsuka Pharma (TYO: 4768) of Japan snagged marketing rights to Iclusig, a leukemia drug developed by ARIAD Pharmaceuticals (NASDAQ: ARIA ), for Japan, China and eight other Asian countries (see story ). Otsuka will pay $77.5...
CRME: 9.25 (+0.19), ARIA: 6.87 (+0.05)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 8:18AM CST
CYTK: 8.01 (+1.11), JRJC: 5.32 (-0.24), RDN: 16.72 (-0.11), CHK: 19.57 (-0.07), VNDA: 14.32 (-0.19), DRL: 3.95 (-0.09), ARIA: 6.87 (+0.05), ICLD: 2.92 (-0.02), NQ: 3.91 (-0.10)
Ariad Pharma inks commercialization deal in Asia
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 6:43AM CST
ARIA: 6.87 (+0.05)
ARIAD and Otsuka Announce Co-Development and Commercialization Agreement for Iclusig to Treat Leukemias in Japan and Nine Other Asian Countries
Business Wire - Tue Dec 23, 6:00AM CST
--Otsuka to obtain rights in ten Asian countries to Iclusig, a newest-generation treatment for patients with refractory chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia
ARIA: 6.87 (+0.05)
ARIAD To Present at The 33rd Annual J.P. Morgan Healthcare Conference
Business Wire - Mon Dec 22, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the 33rd Annual J.P. Morgan Healthcare Conference being held in San Francisco. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company's business on Wednesday, January 14 at 3:00 p.m. (PT).
JPM: 62.58 (-0.57), ARIA: 6.87 (+0.05)
Adam Feuerstein's 2014 Biotech Stock Report Card (No Grading on a Curve)
at The Street - Fri Dec 19, 8:02AM CST
Good calls: Vertex, InterMune, Chelsea, Galena, Exact Sciences. The bad calls: Avanir, Amarin, Exelixis and the bursting biotech stock bubble.
VRTX: 118.80 (-0.35), GALE: 1.51 (-0.01), EXAS: 27.44 (-1.09), ARIA: 6.87 (+0.05), MNKD: 5.22 (-0.13)
Biotech Stocks Technical Insight -- ARIAD Pharma, Geron, PDL BioPharma, Cytori Therapeutics, and Navidea Biopharma
PR Newswire - Thu Dec 18, 8:15AM CST
Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Geron Corporation (NASDAQ: GERN), PDL BioPharma Inc. (NASDAQ: PDLI), Cytori Therapeutics Inc. (NASDAQ: CYTX), and Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Wednesday, December 17, 2014, surged as the Dow Jones Industrial Average finished at 17,356.87, up 1.69% and the NASDAQ Composite closed at 4,644.31, up 2.12%. The S&P 500 finished the session 2.04% higher at 2,012.89. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Index ended the day at 791.66, up 1.90%, with the index advancing 6.28% in the previous three months. Register for your complimentary reports on these five stocks at:
NAVB: 1.89 (+0.06), CYTX: 0.49 (+0.02), GERN: 3.25 (+0.04), ARIA: 6.87 (+0.05), PDLI: 7.71 (unch)
Does George Soros Think Biotech's Bull Run Is Finally Coming to an End?
George Budwell, The Motley Fool - Motley Fool - Mon Dec 15, 6:45AM CST
To say that biotech stocks have performed well as a group over the last two years is an understatement; they have absolutely crushed the broader markets. For example, the iShares Nasdaq Biotech Index has more than tripled the performance of the ...
SRPT: 14.47 (-0.05), IBB: 303.35 (-1.27), ARIA: 6.87 (+0.05), CELG: 111.86 (-1.68)
SmarTrend Watching for Potential Rebound in Shares of Ariad Pharmaceuticals After 7.76% Loss
Comtex SmarTrend(R) - Thu Dec 11, 4:40PM CST
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $6.34 to a high of $6.88. Yesterday, the shares fell 7.8%, which took the trading range below the 3-day low of $6.80 on volume of 13.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ARIA: 6.87 (+0.05)
Energy Stocks Pare Gains as Crude Oil Closes Below $60 For First Time in Five Years
at The Street - Thu Dec 11, 1:52PM CST
Energy stocks are leading the markets higher, a day after they sparked a selloff.
SPLS: 18.12 (+0.09), DAL: 49.19 (-0.04), XOM: 92.45 (-0.57), COP: 69.06 (-0.87), LLY: 68.99 (-0.65), LULU: 55.79 (+0.04), LUV: 42.32 (+0.15), URBN: 35.13 (+0.06), EBAY: 56.12 (-1.10), AAL: 53.63 (+0.21), ODP: 8.57 (-0.04), ARIA: 6.87 (+0.05), CVX: 112.18 (-0.93), WAG: 76.05 (-0.49), XLE: 79.16 (-0.60)
Nasdaq stocks posting largest percentage decreases
AP - Thu Dec 11, 12:19PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
AMBA: 50.72 (-1.68), LNCO: 10.37 (+0.13), MCEP: 6.31 (+0.53), LAKE: 9.37 (-0.18), CLDN: 19.53 (-0.11), BRID: 7.75 (+0.38), ARIA: 6.87 (+0.05), LINE: 10.13 (+0.04), MIND: 5.93 (-0.06), DGLY: 15.32 (-0.56), ALLT: 9.18 (+0.20), ROSE: 22.31 (+0.28)
Ariad slumps after analyst downgrade
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 9:25AM CST
IBB: 303.35 (-1.27), ARIA: 6.87 (+0.05)
Will Ariad Pharmaceuticals (ARIA) Stock be Affected Today by This Analyst Action?
at The Street - Thu Dec 11, 8:14AM CST
Shares of Ariad Pharmaceuticals (ARIA) are down after Credit Suisse downgraded the global oncology company to 'underperform' from 'neutral' and lowered its price target to $6 from $8.
ARIA: 6.87 (+0.05)
Downgrade Alert for Ariad Pharmaceuticals (ARIA)
Comtex SmarTrend(R) - Thu Dec 11, 6:54AM CST
Ariad Pharmaceuticals (NASDAQ:ARIA) was downgraded from Neutral to Underperform at Credit Suisse today. The stock closed yesterday at $7.02 on volume of 4.6 million shares, below average daily volume of 6.3 million. In the past 52 weeks, Ariad Pharmaceuticals share prices have been bracketed by a low of $3.80 and a high of $9.83 and closed yesterday at $7.02, 85% above that low price. Over the last five market days, the 200-day moving average (MA) has gone down 0.3% while the 50-day MA has advanced 1.5%.
ARIA: 6.87 (+0.05)
Uptrend Call Working As Ariad Pharmaceuticals Stock Rises 22.6% (ARIA)
Comtex SmarTrend(R) - Tue Dec 09, 5:08PM CST
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on October 29th, 2014 at $5.92. In approximately 1 month, Ariad Pharmaceuticals has returned 22.57% as of today's recent price of $7.25.
ARIA: 6.87 (+0.05)
